Label change for Elan's MS-drug permits safer use

24.01.12 Weston/Dublin - The focus for Tysabri, the MS drug jointly developed by Irish Elan and US-Biogen, has become a little more accurate. The US Food and Drug Administration (FDA) stated that the occurrence of antibodies against the... more

Alzheimer alliance

13.12.11 Dublin/Cambridge – The University of Cambridge and Irish drugmaker Elan Pharmaceutical Inc. have joined forces in the battle against Alzheimer’s Disease. Together, the two will create the Cambridge-Elan Centre for Research... more

Fragmented alliance in cancer drugs

07.12.11 Uppsala/Craigavon - Irish Almac trusts a Swedish platform to develop new cancer drug candidates. As Uppsala-based Beactica announced on Tuesday, its Sprint-technology will be used to identify fragment hits against a number of... more

Tibotec enters clinical collaboration with BMS in hepatitis C

05.12.11 Dublin /New York – Irish Tibotec Pharmaceutical Ltd and Bristol-Myers Squibb (BMS) have entered into a clinical collaboration for the treatment of chronic hepatitis C infections with a combination of BMS’ NS5A replication complex... more

University of Cambridge and Elan Pharmaceutical team up against AD

29.11.11 Dublin/Cmbridge (UK) – The University of Cambridge and Irish drugmaker Elan Pharmaceutical have joined forces in the battle against Alzheimer’s Disease. Together, the two will create a new research centre dedicated to... more